Vaccinex Reports Improved Immunity Correlating With Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

GlobeNewswire11/05 21:30

Vaccinex Shares Are Trading Lower. The Company Provided an Update on New Clinical Findings From Its SIGNAL-AD Phase 1b/2 Trial of Pepinemab Antibody in Alzheimer's Disease.

Benzinga11/01 00:45

Vaccinex Shares Halted On Circuit Breaker To The Upside, Stock Now Up 6.20%

Benzinga10/31 22:02

Vaccinex Stock Spikes On 'Promising' Data On Alzheimer's Drug Study: Retail Sentiment Brightens

Barchart10/25 19:18

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

GlobeNewswire10/24 20:30

Vaccinex Files for Secondary Stock Offering

Seeking Alpha10/17 05:01